|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2004-11-24
|
|
pubmed:abstractText |
Leuvectin (Vical Inc., San Diego, CA) is a gene transfer product in which a plasmid encoding the human interleukin-2 (IL-2) gene is complexed with the cationic lipid 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine (DMRIE/DOPE). In the current study, the authors investigated the safety and efficacy of in situ vaccination with Leuvectin in patients with metastatic renal cell carcinoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:AkporiayeEmmanuel TET,
pubmed-author:BurchPatrick APA,
pubmed-author:FrytakStephenS,
pubmed-author:GalanisEvanthiaE,
pubmed-author:KaurJudith SJS,
pubmed-author:LewisBradleyB,
pubmed-author:OkunoScott HSH,
pubmed-author:PeethambaramPrema PPP,
pubmed-author:PitotHenry CHC,
pubmed-author:RichardsonRonald LRL,
pubmed-author:RubinJosephJ,
pubmed-author:SpierCatherineC,
pubmed-author:UnniKrishnan KKK
|
|
pubmed:copyrightInfo |
(c) 2004 American Cancer Society
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2557-66
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15517589-Adult,
pubmed-meshheading:15517589-Aged,
pubmed-meshheading:15517589-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15517589-Cancer Vaccines,
pubmed-meshheading:15517589-Carcinoma, Renal Cell,
pubmed-meshheading:15517589-Female,
pubmed-meshheading:15517589-Gene Expression Regulation,
pubmed-meshheading:15517589-Gene Therapy,
pubmed-meshheading:15517589-Gene Transfer Techniques,
pubmed-meshheading:15517589-Humans,
pubmed-meshheading:15517589-Interleukin-2,
pubmed-meshheading:15517589-Kidney Neoplasms,
pubmed-meshheading:15517589-Lipids,
pubmed-meshheading:15517589-Male,
pubmed-meshheading:15517589-Middle Aged,
pubmed-meshheading:15517589-Phosphatidylethanolamines,
pubmed-meshheading:15517589-Plasmids,
pubmed-meshheading:15517589-Quaternary Ammonium Compounds,
pubmed-meshheading:15517589-Survival Analysis
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
|
|
pubmed:affiliation |
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA. galanis.evanthia@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
